• Overview
  • Eligibility
  • More info
  • Locations

Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion (NCT03025360)

Larotrectinib (LOXO-101) expanded access is for patients with cancer with a NTRK1, NTRK2, or NTRK3 gene fusion who are ineligible for an ongoing larotrectinib (LOXO-101) clinical trial or have other considerations that prevent access to larotrectinib (LOXO-101) through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion.
  • Drug: larotrectinib
    Open-label expanded access, capsules or liquid formulation
    • LOXO-101
Ages eligible for Study
all
Genders eligible for Study
All
Accepts Healthy Volunteers
Inclusion Criteria:
  • Diagnosis of cancer with a NTRK1, NTRK2, or NTRK3 gene fusion
  • Are unable to participate in an ongoing larotrectinib (LOXO-101) clinical trial
  • Willing and able to provide written, signed informed consent
  • Medically suitable for treatment with larotrectinib (LOXO-101)
Exclusion Criteria:
  • Currently enrolled in an ongoing clinical study of larotrectinib (LOXO-101) or another TRK inhibitor
Status:
available
Type:
Expanded Access
Phase:
-
Start:
01 January, 0001
Updated:
15 January, 2017
Participants:
0
A girl giving information about available additional trials.

FindMeCure helps you find, understand and join clinical trials from all over the world.

There are more clinical trials for your condition!